2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetologia Jg. 63; H. 2; S. 221 - 228
Hauptverfasser: Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2020
Springer Nature B.V
Schlagworte:
Agonists
Cardiovascular diseases
Cardiovascular Diseases - metabolism
Clinical trials
Congestive heart failure
Consensus Report Update
Creatinine
Death
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Epidermal growth factor receptors
Europe
GLP-1 receptor agonists
Glucagon
Glucagon-Like Peptide-1 Receptor - agonists
Glycated Hemoglobin A - metabolism
Health risk assessment
Heart failure
Human Physiology
Humans
Hyperglycemia
Hypoglycemia
Hypoglycemic Agents - therapeutic use
Internal Medicine
Kidney diseases
Medicine
Medicine & Public Health
Metabolic Diseases
Patient-centered care
Societies, Medical
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
United States
United States
Europe
Heart failure
Patient-centred care
Glucose-lowering therapy
Hypoglycaemia
Cardiovascular disease
Chronic kidney disease
Type 2 diabetes mellitus
Guidelines
ISSN:0012-186X, 1432-0428, 1432-0428
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA 1c or individualised HbA 1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min −1 [1.73 m] −2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0012-186X
1432-0428
1432-0428
DOI:10.1007/s00125-019-05039-w